image description

Tag: Teodora Staeva

Lupus and COVID-19: What You Need to Know – LIVE WEBCAST May 21 at 6 PM ET

Since the arrival of the novel coronavirus, lupus and the most prescribed drug used to treat it – hydroxychloroquine – have been thrust into the public spotlight despite the mounting scientific evidence that drug does not appear to improve clinical outcomes in patients with COVID-19. What has been talked about less is what the impact […] Read More

LRA Researchers Star at ACR/ARP – Part 2

Last week we gave you only half the story of what scientists funded by the Lupus Research Alliance (LRA) shared at 2019 ACR/ARP. So many studies were presented that we needed to bring you Part 2 to expand our coverage of the major discoveries your donations have made possible. And a Part 3 is yet […] Read More

LRA-Funded Discovery May Benefit Alzheimer’s Disease

August 1, 2019 A new study by LRA Distinguished Innovator Award recipient Dr. Douglas Green of St. Jude Children’s Research Hospital in Memphis, TN, and colleagues may have uncovered a new way to treat Alzheimer’s disease. The research, highlighted recently in Forbes magazine and published in the journal Cell, identified one of the brain’s mechanisms […] Read More

Updates in Lupus Clinical Research from the LUPUS 2019 Meeting

April 11, 2019 The Lupus Research Alliance is pleased to share the results from four clinical trials presented at LUPUS 2019.  These studies continue to push our way forward toward new and improved treatments to help the lupus community. There’s a Silver Lining in New Belimumab Results Jim Oates, MD, Medical University of South Carolina, […] Read More

Promising Results from AMP

October 30, 2018 The Lupus Research Alliance is one of the sponsors of the Accelerating Medicines Partnership in Rheumatoid Arthritis and Lupus (AMP RA/Lupus), a public-private partnership between the National Institutes of Health, the U.S. Food and Drug Administration and several pharmaceutical companies and nonprofit organizations.  AMP aims to speed the development of new therapies, […] Read More

Positive Early Results for BIIB059 as New Treatment Strategy

February 28, 2019 Proteins of the immune system, known as type I interferons, are responsible in part for manifestations of lupus. For this reason, type I interferons are a very attractive target for lupus drug development. In 2015, excitement surrounded the release of positive phase II data with anifrolumab, a therapeutic antibody that blocks type […] Read More

LRA Research Director Presents at ACR Roundtable

October 22, 2018 Our Research Director, Dr. Teodora Staeva, presented at the “Meet the Funders: NIH & Foundation Roundtable Grant Discussion” October 22 at the American College of Rheumatology (ACR) annual meeting. Dr. Staeva spoke about the Lupus Research Alliance many grant programs available to scientists including the  Target Identification in Lupus, Novel Research Grant, Analysis of Lupus […] Read More